Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora
27 de mayo de 2015 actualizado por: NovaBay Pharmaceuticals, Inc.
A Multicenter Randomized, Double-Masked Study Comparing the Efficacy of Novabay iLid Cleanser Versus Vehicle on Ocular Skin Flora
This study is designed to evaluate the effect of Novabay iLid Cleanser, as compared to its Vehicle, on the ocular skin flora.
In the pre-randomization phase, subjects will receive a single application of open-label NovaBay iLid Cleanser.
In the randomization phase of Stages 1 and 2, subjects will self-treat with masked Investigational Product twice daily for ten (10) days.
Descripción general del estudio
Estado
Desconocido
Condiciones
Intervención / Tratamiento
Descripción detallada
This is an adaptive design, randomized, double-masked, vehicle-controlled, multicenter, parallel group study with two treatment arms: NovaBay iLid Cleanser ("Cleanser") and Cleanser Vehicle ("Vehicle").
The study will be conducted in two Stages, each preceded by a pre-randomization phase. Randomization of Cleanser:Vehicle will be 1:1 and 2:1 in Stages 1 and 2 respectively.
In the pre-randomization phase for Stages 1 and 2, subjects who meet all inclusion and no exclusion criteria will be evaluated by clinical examination at a single visit prior to having ocular skin specimens taken before and after treatment with open-label Cleanser.
In the randomization phase for both Stages 1 and 2, subjects who meet all inclusion and no exclusion criteria will be randomized and evaluated at three visits:
- Visit 1: Screening, Day 1
- Visit 2: Day 11 (+2) End of Treatment (EOT)
- Visit 3: Day 18 (±2) Post Treatment Evaluation/Exit Subjects will have ocular skin specimens taken at Visit 1, Day 1. The specimens will be collected before and 20 minutes after the first application of the study Investigational Product performed by study personnel.
Tipo de estudio
Intervencionista
Inscripción (Anticipado)
100
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85032
- Reclutamiento
- Ophthalmic Research Consultants of Arizona
-
Contacto:
- Andrea Sarich
- Número de teléfono: 602-549-2020
- Correo electrónico: sarich.andrea@gmail.com
-
Investigador principal:
- Arthur Epstein, OD
-
-
California
-
San Leandro, California, Estados Unidos, 94577
- Reclutamiento
- Turner Eye Institute
-
Contacto:
- Erika Chang
- Número de teléfono: 800-339-2733
- Correo electrónico: echang@turnereye.com
-
-
North Carolina
-
Winston Salem, North Carolina, Estados Unidos, 27101
- Reclutamiento
- James D. Branch, MD
-
Contacto:
- Elaine Acosta
- Número de teléfono: 336-721-4711
- Correo electrónico: emaeye@hotmail.com
-
Investigador principal:
- James Branch, MD
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
6 años y mayores (Niño, Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Male or female, of any race, at least 6 years of age.
Must be eligible for a recommendation to use eye lid cleansing/scrubs for:
- Signs of acute or chronic blepharitis, such as eye lid debris (sleeves, collorates, flakes, crusting) requiring eye lid cleansing/scrubs, and/or
- Signs consistent with mild, moderate, or severe meibomian gland disease (MGD) such as dilated and blocked glands with inspissated secretions sluggish or stagnant upon expression.
- Must be able to read, understand and sign an informed consent form that has been approved by an Institutional Review Board/Ethics Committee. If subject is less than 18 years of age, the informed consent must be signed and dated by subject's legally authorized representative (parent or guardian). Assent to participate should also be obtained from subjects under 18 years of age if required by local regulation.
- Must agree to comply with the visit schedule and other requirements of the study. The parent or guardian must agree to ensure compliance of subjects less than 18 years of age.
- Must agree to remove contact lenses, if applicable, for 15 minutes before and after application of the study Investigational Product.
- Must agree for the duration of the study to refrain from use of makeup/cosmetic products used around the eye(s) such as eye liner, mascara, and/or shadow, foundation or powder. Use of such products is allowed if the eyelid skin area is avoided.
Exclusion Criteria:
- Presence of signs and symptoms of bacterial or allergic conjunctivitis or allergic dermatitis at the Day 1 Visit.
- Suspected fungal, viral, Chlamydia or Acanthamoeba infection based on clinical diagnosis.
- Visual acuity not correctable to 1.0 LogMAR or better (equivalent to Snellen 20/200) in either eye using either a Snellen or ETDRS chart.
- Use of any topical ocular medications including tear substitutes during study participation.
- Use of any preserved or non-preserved glaucoma medications during the 14 days prior to Visit 1 and anticipated use during study participation.
- Presence of nasolacrimal duct obstruction.
- Presence of a punctal plug in either eye.
- Any systemic or ocular disease or disorder, complicating factors or structural abnormality that would negatively affect the conduct or outcome of the study.
- Presence of active inflammation and/or active structural change in the cornea, iris or anterior chamber at the Day 1 visit.
- Use of any topical ocular or oral antimicrobial agent within the 3 days prior to Day 1 visit.
- Use of topical ocular corticosteroids or non-steroidal topical ocular anti-inflammatories (NSAIDs), within 3 days prior to study entry and during the trial.
- Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%) in either eye during the trial.
- Any current immunosuppressive disorder (e.g., HIV positive), or use of immunosuppressive therapy (including chemotherapy).
- Participation in any other investigational clinical study within 30 days prior to study enrollment.
- Any subject who is on staff at the investigational site or is a family member of staff personnel.
- Additionally, the Investigator or Medical Monitor may declare any subject ineligible for a sound medical reason.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: iLid Cleanser (Avenova)
iLid Cleanser - applied 2 times per day for 10 days
|
Application of iLid Cleanser to reduce bacterial load on the lid and lash margins
Otros nombres:
|
|
Comparador de placebos: iLid Cleanser Vehicle
iLid Cleanser Vehicle - applied 2 times per day for 10 days
|
Application of iLid Cleanser to reduce bacterial load on the lid and lash margins
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Microbiological efficacy
Periodo de tiempo: 20 minutes after application of test article
|
Quantitative assessment of numbers of recoverable bacteria before versus after application of test article
|
20 minutes after application of test article
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Ocular Signs
Periodo de tiempo: Assessed on Visit 1(Day 1), Visit 2 (Day 11) and Visit 3 (Day 18)
|
lid erythema, lid swelling, lid crusting and debris on lashes, bulbar and palpebral conjunctival injection, and meibomian gland secretions (after expression)
|
Assessed on Visit 1(Day 1), Visit 2 (Day 11) and Visit 3 (Day 18)
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Director de estudio: David W. Stroman, Ph.D., NovaBay Pharmaceuticals, Inc.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de mayo de 2015
Finalización primaria (Anticipado)
1 de enero de 2016
Finalización del estudio (Anticipado)
1 de mayo de 2016
Fechas de registro del estudio
Enviado por primera vez
26 de mayo de 2015
Primero enviado que cumplió con los criterios de control de calidad
27 de mayo de 2015
Publicado por primera vez (Estimar)
28 de mayo de 2015
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
28 de mayo de 2015
Última actualización enviada que cumplió con los criterios de control de calidad
27 de mayo de 2015
Última verificación
1 de mayo de 2015
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CM-01-14
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre iLid Cleanser
-
Johnson & Johnson Consumer Inc. (J&JCI)Terminado